Moderna's cancer vaccine breakthrough could reshape its growth trajectory

Moderna's stock surged about 177% after news that its personalized mRNA cancer vaccine intismeran, in combination with Merck's Keytruda, reduced melanoma recurrence in a Phase 3 trial, signaling a potential shift for the biotech beyond infectious disease. Analysts from Jefferies, Bank of America, Citi, and JPMorgan call the result a watershed for Moderna's oncology outlook, with upside if label expansions and cross-indication uptake materialize, though questions remain about dataset completeness and commercial adoption. Fuller data and presentations are expected at the upcoming ESMO meeting, while the stock cooled slightly in premarket trading after yesterday's rally.